Cierra Johnson, MD
Family Medicine · Salina, KSNPI 1013327659
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $442 and has fallen 61.3% since, to $171 in 2025.
Across 112 payments — averaging $14.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$261
- Johnson & Johnson$204
- Novo Nordisk$175
- AbbVie$161
- Astellas Pharma US Inc$124
- Amgen$118
- plus $593 from 16 others
What the payments were for
- Food & beverage$1,62299%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 20 | $261 |
| Johnson & Johnson | 13 | $204 |
| Novo Nordisk | 12 | $175 |
| AbbVie(2 entities) | 9 | $161 |
| Astellas Pharma US Inc | 10 | $124 |
| Amgen | 9 | $118 |
| GSK | 5 | $89 |
| Novartis | 5 | $81 |
| Esperion Therapeutics, Inc. | 4 | $80 |
| AstraZeneca | 5 | $69 |
| Lilly USA, LLC | 3 | $46 |
| Boston Scientific | 2 | $37 |
| Merck | 3 | $37 |
| Viiv Healthcare Company | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Sanofi-aventis U.S. LLC | 2 | $24 |
| Organon | 1 | $16 |
| Corcept Therapeutics | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Mylan Specialty L.p. | 1 | $11 |
| Medtronic | 1 | $11 |
| Shire North American Group Inc | 1 | $11 |
How this compares
$1,636 in reported general payments places this provider in the 70th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 62 | $75,348 |
| EliquisApixaban | 66 | $63,488 |
| OzempicSemaglutide | 48 | $54,766 |
| MounjaroTirzepatide | 41 | $39,088 |
| XareltoRivaroxaban | 27 | $30,974 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $23,867 |
| JardianceEmpagliflozin | 25 | $20,219 |
| MyrbetriqMirabegron | 37 | $16,043 |
| JanuviaSitagliptin Phosphate | 13 | $14,734 |
| EntrestoSacubitril/Valsartan | 15 | $11,699 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 25 | $8,014 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 28 | $6,208 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,132 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 140 | $4,610 |
| Mesalamine | 18 | $4,240 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $46 | $114,436103 claims |
| PfizerEliquis, Abrysvo | $261 | $71,50391 claims |
| Novo NordiskOzempic | $175 | $54,76648 claims |
| GSKTrelegy Ellipta, Shingrix, Anoro Ellipta, Arnuity Ellipta | $89 | $39,11592 claims |
| Johnson & JohnsonXarelto | $204 | $30,97427 claims |
| Astellas Pharma US IncMyrbetriq | $124 | $16,04337 claims |
| MerckJanuvia | $37 | $14,73413 claims |
| NovartisEntresto | $81 | $11,69915 claims |
| AstraZenecaSymbicort | $69 | $3,26414 claims |
| AbbVieSynthroid | $161 | $1,35527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Salina
- Bradley HarrisonManhattan$314K
- Mila MeansWichita$241K
- Scott AveryJunction City$195K
- Kent KiracofeManhattan$189K
- Terry McGeeneyLeawood$147K
- Cole GillenwaterWichita$62K
- David StricklandLawrence$53K
- Kyle PlatzManhattan$51K
- Eric AspinwallKansas City$28K
- Hai TruongWichita$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.